Neurology Central

Latest erenumab trial signals hope for refractory migraine sufferers

0
Amgen (CA, USA) has announced finding from its latest trial investigating the drug Aimovig™ (erenumab) for the treatment of episodic migraines in patients who have not responded to previous treatment.
To view restricted content, please:
Share:

Leave A Comment